Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

March 27, 2007; 68 (13) Views & Reviews

Ethnic variation in the incidence of ALS

A systematic review

Simon Cronin, Orla Hardiman, Bryan J. Traynor
First published March 26, 2007, DOI: https://doi.org/10.1212/01.wnl.0000258551.96893.6f
Simon Cronin
From the Irish ALS Research Group (S.C., O.H.), Neurology Department, Beaumont Hospital, Dublin, Ireland; and Section on Developmental Genetic Epidemiology (B.J.T.), National Institutes of Health, Bethesda, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orla Hardiman
From the Irish ALS Research Group (S.C., O.H.), Neurology Department, Beaumont Hospital, Dublin, Ireland; and Section on Developmental Genetic Epidemiology (B.J.T.), National Institutes of Health, Bethesda, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan J. Traynor
From the Irish ALS Research Group (S.C., O.H.), Neurology Department, Beaumont Hospital, Dublin, Ireland; and Section on Developmental Genetic Epidemiology (B.J.T.), National Institutes of Health, Bethesda, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Ethnic variation in the incidence of ALS
A systematic review
Simon Cronin, Orla Hardiman, Bryan J. Traynor
Neurology Mar 2007, 68 (13) 1002-1007; DOI: 10.1212/01.wnl.0000258551.96893.6f

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1142

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Background: The findings of recent genetic polymorphism studies in ALS suggest that the influence of genetic risk factors for the disease may vary by ethnicity. It is now widely accepted that the incidence of ALS is uniform across Caucasian populations, but whether racial variation across other ethnicities exists remains unknown.

Method: Systematic review of the known literature on the incidence, prevalence, and mortality of ALS across all ethnicities. To facilitate comparison, studies were grouped according to the type of data presented and examined for sources of case ascertainment and inclusion criteria.

Results: The literature search identified 61 publications. Lower standardized incidence rates were observed in Asian than Caucasian populations. Within the United States, several incidence and mortality studies have identified lower ALS frequency among African American and Hispanic populations than among non-Hispanic Caucasians. These observations are supported by the other data sources.

Conclusions: The incidence of ALS may be lower among African, Asian, and Hispanic ethnicities than among whites. We conclude with proposals for a prospective epidemiologic study concentrating on non-Caucasian populations.

Whether ALS frequency varies by ethnicity has been a source of controversy for many decades.1–3 Recent genetic polymorphism studies have suggested that ethnic background may indeed modify predisposition to ALS.4–6 Therefore, a careful examination of the population frequency of ALS across different ethnicities is both timely and desirable, as such data may reveal at-risk ethnicities as candidates for further genetic study.

With this in mind, we performed a systematic review of the known data concerning ethnic variation in the occurrence of ALS. We had the dual aims of summarizing the known data and of appraising which methodological approaches are most likely to yield valuable information in future studies.

Methods.

Data extraction.

A Medline literature search was performed to identify all published studies on ALS incidence, prevalence, or mortality from 1966 to March 2006, using the MeSH terms “ALS,” “motor neuron(e) disease,” “Lou Gehrig’s disease,” “Charcot’s disease,” “incidence,” “prevalence,” “mortality,” and “epidemiology.” Additional references were sought from article citations. Data were extracted by a single investigator (S.C.) and reviewed by two ALS neurologists (O.H., B.J.T.). Where groups reported data from a single population on more than one occasion, the most recent study was included.7–10 Reports from high-incidence clusters (such as the Guam/Kii Peninsula of Japan) were excluded. Included studies were then grouped according to the type of data presented: 1) studies providing crude incidence or prevalence rates; among these, studies providing age- and sex-adjusted incidence rates allowing standardized comparisons with other countries were identified; 2) studies that reported data stratified by ethnic group within a single population; 3) migration studies; and 4) other mortality studies. A study may appear in more than one category. To facilitate meaningful comparison between studies, a key to the sources of case ascertainment and diagnostic criteria11 for inclusion is provided in table E-1 (available on the Neurology Web site at www.neurology.org).

Data analysis.

Incidence and prevalence rates are crude and unadjusted unless otherwise stated. Where published data allowed, incidence rates for the 45- to 74-year-old age bracket were calculated and age- and sex-adjusted to the US 2000 standard population by the direct method.12 This age band reflects the peak ages of presentation where ascertainment is likely to be complete and has been used by a number of other authors.2,13 CIs were calculated assuming Poisson distribution. Within individual studies, race-specific confidence limits have been calculated according to the size of the ethnic population during the time period studied (information from the US Census Bureau). Ethnic and racial categories were defined according to NIH guidelines (1997 Office of Management and Budget Directive 15). Significance indicates p < 0.05.

Results of data extraction.

Classification of included studies.

Sixty-one ALS epidemiologic studies satisfied criteria for consideration in this paper. Forty-five studies7–10,13–53 provided crude incidence or prevalence data for ALS (table E-1). Stratified by region, there were 27 studies from Europe,9,13,29–53 five from Central and South America,14–18 four from North America and Canada,19–21 two from Asia,8,22 two from the Pacific,23,24 three from Africa,25–27 and single studies from the Middle East7 and Russia.28 Twenty-two of these studies provided sufficient incidence data for age and sex adjustment to a standard population 7–9,13,19–22,25,30–32,34,35,37,42,43,49–52,54. Six studies presented incidence or mortality of motor neuron disease (MND) stratified by ethnicity within the observed population.19,21,24,55–57 Three migration studies were considered.58–60 Twenty mortality studies were identified16–18,20,22,24,36,39,40,49,55,56,61–68.

Sources of case ascertainment.

Among studies of ALS incidence and prevalence (table E-1), 17 had a single source of case ascertainment7,10,14,16,18,26,27,33,37,39,40,43,44,46,48,50,53 and six had two.17,20,24,25,30,35 Only seven register-based studies of ALS incidence have been published to date, five of which were based in the Caucasian populations of Europe and North America.9,13,19,31,32 The other prospective population-based studies described the epidemiology of ALS in Japan and Uruguay.8,15 The majority of studies in non-Caucasian populations tended to be smaller and to use less reliable data sources.

Inclusion criteria of cases.

Heterogeneity in the definition of MND was observed among studies. More studies included progressive spinal muscular atrophy in the calculation of incidence rates than excluded it (table E-1). Three studies included juvenile spinal muscular atrophy and consequently may have overestimated the occurrence of MND.26,27,36

Limitations of the data.

Further comments and critique of the studies discussed below are provided in table E-1.

Results.

Studies that provide incidence or prevalence rates by region (table E-1).

Within the Caucasian populations of Europe and North America, the highest reported crude incidence of ALS was 2.4 per 100,000 person-years in Middle Finland, and the lowest reported was 0.6 in Italy. Most studies in European and American populations observed a crude incidence above 1 per 100,000 person-years. Outside of Europe and North America, high incidence was noted only from a single South American study15 and in the mixed population of Hawaii.24 The remainder of studies outside Europe and North America document a crude incidence below 1 per 100,000 person-years. However, there was a wide disparity between the epidemiologic methods employed in these regions compared to Europe and North America (table E-1).

To facilitate meaningful comparisons, age- and sex-adjusted incidence rates from 22 of the epidemiologic studies were standardized to the 2000 US population (table 1). A number of observations can be made. First, prospective designs with multiple sources of case ascertainment provide higher estimates than retrospective studies performed in the same populations. Second, the incidence of ALS across Europe is remarkably uniform, as demonstrated by four prospective, population-based studies from Ireland, Scotland, and Italy.9,13,31,32 Finally, only a limited number of the adjustable studies examine incidence of ALS among non-Caucasian populations.8,22,25

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1 Comparison of incidence studies of ALS, standardized to the 2000 US population using the 45 to 74 age band

Only three epidemiologic studies of ALS have been performed in black African populations25–27 (table E-1). Among these, a single incidence study,25 from Benghazi in Libya, was available. This reports an apparently low crude incidence rate of 0.87 per 100,000 person-years. However, Libya has a young population, with 81% younger than the age of 40,25 and thus the standardized incidence for the 45 to 74 age band of 4.6 per 100,000 person-years (95% CI: 2.9 to 6.8) does not differ from rates seen across Southern Europe (table 1). Conversely, marked differences in ALS incidence are not to be expected between Libya and Southern Europe because the Libyan population encompasses mixed descendants of Arabs, Europeans, and Africans, and <1% are of black African origin.25 There have been no well-conducted ALS incidence studies elsewhere in Africa.

There are two published studies concerning the incidence of ALS in Asian populations (table E-1 and table 1). A large, prospective incidence study of ALS on Hokkaido Island, Japan8 reported a standardized incidence for the 45 to 74 age band of 2.0 per 100,000 person-years (95% CI: 1.6 to 2.4). The lowest incidence observed by prospective studies in Caucasian populations is 3.8 per 100,000 person-years (95% CI: 3.2 to 4.4; Puglia, Italy), indicating a significant difference. This apparently lower ALS incidence among Asian populations is supported by a retrospective study of ALS among Hong Kong Chinese,22 in which the standardized ALS incidence for the 45 to 74 age band was 0.8 (95% CI: 0.5 to 1.0).

Regarding Central and South American populations, there has been speculation that a “resistance” to ALS exists among Mexicans, based on a study performed in Mexico City reporting an incidence of 0.4 per 100,000.17 Low incidence rates have also been reported from other Hispanic white populations in South America,14,16,18 particularly a population-based prospective study from Uruguay (1.4 per 100,000 person-years15). However, these studies had several methodologic flaws that may explain their observations (table E-1). Furthermore, it may be difficult to assign a single rate under the term Hispanic, as individual populations in Central and South America comprise different admixtures of Spanish, European, Amarinidian, Carthagian, and Arab peoples.69 Thus, the term Hispanic is likely to be a less homogeneous and useful epidemiologic category than Asian or African.69

ALS epidemiology studies that stratified their findings by ethnicity.

Differences in case finding methodology and population demographics hinder comparison of ALS incidence between different continents. An alternative approach is to search for ethnic variation within a single study employing a uniform method of case ascertainment within a racially diverse population. Six such studies, mainly from the United States, are summarized in table 2.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2 Incidence and mortality studies of motor neuron disease that stratified their findings by ethnicity

A prospective, population-based study of ALS in Washington State reported lower age-adjusted incidence rates among nonwhites (mostly African American) compared to the white population, although the 95% CIs markedly overlapped.19 In contrast, a retrospective incidence study in Harris County, TX, found similar incidence rates between African Americans and non-Hispanic whites, but was underpowered to exclude a decreased incidence among blacks.21

Three population-wide ALS mortality studies have been published on the United States (table 2). Mortality studies have the advantage of providing a larger population for observation than localized epidemiologic studies. All these have reported a lower mortality rate among the Hispanic and African American populations when compared to the white population. It must be remembered, however, that limited access to health care among African Americans may have impeded case ascertainment.70,71

Finally, an incidence study from the Hawaiian Islands stratified its findings by Filipino, Japanese, and Caucasian ethnicity.24 In contrast to the lower incidence of ALS observed in other Asian studies,8,22 there was no significant difference in ALS incidence between Japanese and white ethnic subgroups.

Migration studies.

Migration studies compare the incidence or mortality from ALS among ethnic subgroups that have migrated to a single location. A study of immigrants to London during the 10-year period 1979 to 1988 showed ALS mortality rates to be lower among Asian (standardized mortality ratio [SMR] = 37.6%), East African (SMR = 55.5%), Caribbean (SMR = 73.6%), and West African (SMR = 76.9%) immigrants to London than among native English.58 In contrast, white immigrants from the Indian subcontinent had the expected ALS mortality rate (SMR = 113%). However, the denominators of ethnic populations were not known for that time period and ethnicity was assigned based on the individual’s name.

A further migration study reported a lower ALS incidence among Afro-Asians who had migrated to Israel (standardized incidence ratio = 83%) when compared to the native Israeli Caucasian population.59

A migration study in northwestern Italy showed a higher incidence of ALS for Southern Italian and other European immigrants to northern Italy than the native population.60 Prospective studies have since demonstrated a uniform incidence across the Caucasian populations of Europe, highlighting the difficulties in interpreting migration study data. Immigrant populations may not be representative of the nonimmigrant population of the same ethnic background1 and migration studies do not rule out the existence of environmental factors in the home country.

Mortality studies.

Crude ALS mortality rates reported by 20 studies from 22 ethnically diverse populations are presented in table 3. Of these, five examined rates in the Hispanic Caucasian populations of Central and South America,16–18,66,68 and three examined rates in Asian populations.22,65,67 Lower mortality rates are consistently observed in Hispanic and Asian countries compared to Caucasian populations. However, mortality studies are by definition based on a single source of data. Local variation exists in death certificate coding, further complicated by changes to the International Classification of Diseases in 1979 that have seen separate codes for ALS, progressive bulbar palsy, and progressive muscular atrophy amalgamated as a single code for MND.2 Furthermore, some mortality studies only include cases where MND is listed as the underlying cause of death, whereas others accept any cases where MND appeared anywhere on the death certificate. Overall, mortality studies are more suited to determining the trend of a disease over time within the same country, rather than international comparisons.3

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 3 Comparison of worldwide mortality rates from ALS

Discussion.

Systematic review of 61 publications demonstrates uniform occurrence of ALS across the Caucasian populations of Europe and North America. By contrast, available epidemiologic data suggest that the incidence of ALS is lower among African, Asian and Hispanic ethnicities than among Caucasians. It is difficult to draw firm conclusions, as there is methodologic heterogeneity among studies performed in non-Caucasian populations.

The performance of adequately designed epidemiologic studies in developing countries is hindered by the lack of access to adequate medical care. Even in the United States, underascertainment of neurodegenerative diseases among ethnic minorities70,71 may account for apparent racial variation in ALS frequency. In other regions, cultural factors complicate complete case ascertainment, such as the case with cultural medicine in Hong Kong.22 Finally, life expectancy is generally lower outside of the developed world, and an earlier age at death from infectious or cardiovascular diseases may limit the size of the older, more susceptible population.72,73

Knowledge of how ethnicity modifies an individual’s risk of developing ALS may provide important insights into the pathogenesis of this fatal neurodegenerative condition. Variation in the incidence with ethnicity would support the notion that genetic factors play a dominant role in the pathogenesis of the disease. Such information would have direct consequences for ethnicity matching in the design of genetic studies. If the risk of ALS is higher in a particular ethnic group, then that population should be prioritized for study, as their higher genetic burden might facilitate mutation detection. Different risks of disease in different populations are also the basis of genetic admixture studies, a powerful technique to map susceptibility genes in interbred populations of high- and low-risk racial groups.

Proposals for the design of an epidemiologic study to address ethnic variation in ALS frequency.

  1. Study design: Prospective study designs provide higher disease rate estimates than comparable retrospective studies in the same populations (table 1), and are the preferred method.

  2. Population size: The relative rarity and rapidly fatal course of ALS mean that a study with minimum of 3 to 5 years of follow-up of a population no smaller than one million is required to generate meaningful incidence data within a single ethnic group. If the population is racially heterogeneous, then a larger population cohort will be required to provide differential race-specific incidence data with sufficient precision. For example, in a population composed of two subgroups at an 80:20 ratio, approximately 10 million individuals would require observation for 5 years to detect a 25% difference with certainty (see appendix E-1 for statistical derivation).

  3. Complete case ascertainment: ALS incidence studies without multiple sources of case ascertainment are likely to underestimate disease frequency, as has been demonstrated in Italy (table E-1). In populations of mixed ethnicities, particular attention should be given to case finding among ethnic minorities who may not have access to health insurance or specialist care through liaison with ethnic minority organizations and community-based medical services.

  4. Representation of older age groups: It is desirable that such a study be performed in an area of long-established ethnic diversity so that older age strata are well represented across all ethnic groups.

  5. Uniform diagnostic criteria must be applied. The gold standard El Escorial criteria are suggested, although access to neurophysiologic confirmation may be limited in economically underserved regions.

  6. Reporting of age bands and ethnic subgroups: We suggest that all future studies of ALS incidence report their data stratified by ethnicity and also provide age- and sex-specific incidence rates, so that results can be standardized and meaningful comparisons can be made between different populations.

Footnotes

  • Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the March 27 issue to find the title link for this article.

    This research was supported (in part) by the Intramural Program of the National Institute of Mental Health (BJT).

    Disclosure: The authors report no conflicts of interest.

    Received September 18, 2006. Accepted in final form December 13, 2006.

References

  1. 1.↵
    Brooks BR. Clinical epidemiology of amyotrophic lateral sclerosis. In: Riggs JE, ed. Neuroepidemiology. Philadelphia: WB Saunders, 1996:399–420.
  2. 2.↵
    Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry 1992;55:1106–1115.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Roman GC. Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. J Neurol Neurosurg Psychiatry 1996;61:131–137.
    OpenUrlFREE Full Text
  4. 4.↵
    Gwinn-Hardy K. Racial and ethnic influences on the expression of the genotype in neurodegenerative diseases. In: Cummings J, Hardy J, Poncet M, Christen Y, eds. Genotype–proteotype–phenotype relationships in neurodegenerative diseases. Berlin: Springer, 2005:25–36.
  5. 5.
    Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nat Genet 2006;38:411–413.
    OpenUrlCrossRefPubMed
  6. 6.
    Van Vught PW, Sutedja NA, Veldink JH, et al. Lack of association between VEGF polymorphisms and ALS in a Dutch population. Neurology 2005;65:1643–1645.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Kanaha E, Zilber N. Changes in the incidence of amyotrophic lateral sclerosis in Israel. Arch Neurol 1984;41:157–160.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Moriwaka F, Okumura H, Tashiro K, et al. Motor neuron disease and past poliomyelitis. Geographic study in Hokkaido, the northern-most island of Japan. J Neurol 1993;240:13–16.
    OpenUrlCrossRefPubMed
  9. 9.↵
    PARALS Piemonte and Valle d’Aosta Register for Amyotrophic Lateral Sclerosis. Incidence of ALS in Italy: evidence for a uniform frequency in Western countries. Neurology 2001;56:239–244.
    OpenUrlAbstract/FREE Full Text
  10. 10.
    Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002;59:280–282.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    World Federation of Neurology Subcommittee on Motor Neuron Disease. El Escorial Criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124:(suppl):98–107.
    OpenUrl
  12. 12.↵
    Daly L, Bourke GJ. Interpretation and uses of medical statistics. Oxford: Blackwell Science, 2000.
  13. 13.
    Logroscino G, Beghi E, Zoccolella S, et al. Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. J Neurol Neurosurg Psychiatry 2005;76:1094–1098.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Dietrich-Neto F, Callegaro D, Dias-Tosta E, et al. Amyotrophic lateral sclerosis in Brazil: 1998 national survey. Ar Qneuropsiquiatr 2000;58:607–615.
    OpenUrl
  15. 15.↵
    Vazquez C, Ketzoian C, Legnani C, Rega I, Sanchez N, Perna T. Epidemiology of ALS in Uruguay. Incidence, prevalence and risk factors. Neuroepidemiology 2006;26:182.
    OpenUrl
  16. 16.↵
    Galdames D, Aguilera L, Riveros JM, Arce C. [Epidemiology of amyotrophic lateral sclerosis in Santiago. A retrospective study (author’s transl)]. Rev Med Chil 1980;108:435–439.
    OpenUrlPubMed
  17. 17.↵
    Olivares L, Esteban ES, Alter M. Mexican “resistance” to amyotrophic lateral sclerosis. Arch Neurol 1972;27:397–402.
    OpenUrlCrossRefPubMed
  18. 18.
    Moraes L, Goldbaum M, Silva HCA, Callegaro D. Incidence rate of amyotrophic lateral sclerosis (ALS) in Sao Paulo city, Brazil, 1991-1997. Ar Qneuropsiquiatr 1998;56:343–.
    OpenUrl
  19. 19.↵
    McGuire V, Longstreth WT Jr, Koepsell TD, van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western Washington State. Neurology 1996;47:571–573.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    Hudson AJ, Davenport A, Hader WJ. The incidence of amyotrophic lateral sclerosis in southwestern Ontario, Canada. Neurology 1986;36:1524–1528.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    Annegers JF, Appel S, Lee JR, Perkins P. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985–1988. Arch Neurol 1991;48:589–593.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Fong KY, Yu YL, Chan YW, et al. Motor neuron disease in Hong Kong Chinese: epidemiology and clinical picture. Neuroepidemiology 1996;15:239–245.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Chen KM, Yase Y, eds. Amyotrophic lateral sclerosis in Asia and Oceania. New Zealand: National Taiwan University, 1984:199–238.
  24. 24.↵
    Matsumoto N, Worth RM, Kurland LT, Okazaki H. Epidemiologic study of amyotrophic lateral sclerosis in Hawaii. Identification of high incidence among Filipino men. Neurology 1972;22:934–940.
    OpenUrlFREE Full Text
  25. 25.↵
    Radhakrishnan K, Ashok PP, Sridharan R, Mousa ME. Descriptive epidemiology of motor neuron disease in Benghazi, Libya. Neuroepidemiology 1986;5:47–54.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Osuntokun BO, Adeuja AO, Schoenberg BS, et al. Neurological disorders in Nigerian Africans: a community-based study. Acta Neurol Scand 1987;75:13–21.
    OpenUrlCrossRefPubMed
  27. 27.
    Tekle-Haimanot R, Abebe M, Gebre-Mariam A, et al. Community-based study of neurological disorders in rural central Ethiopia. Neuroepidemiology 1990;9:263–277.
  28. 28.↵
    Khondkarian OA, Bunina TL. On the features of the clinical picture and course of amyotrophic lateral sclerosis. Zh Nevropatol Psikhiatr Im S S Korsakova 1966;66:1457–1461.
  29. 29.
    Ahlstrom G, Gunnarsson LG, Leissner P, Sjoden PO. Epidemiology of neuromuscular diseases, including the postpolio sequelae, in a Swedish county. Neuroepidemiology 1993;12:262–269.
    OpenUrlCrossRefPubMed
  30. 30.
    Murros K, Fogelholm R. Amyotrophic lateral sclerosis in Middle-Finland: an epidemiological study. Acta Neurol Scand 1983;67:41–47.
    OpenUrlCrossRefPubMed
  31. 31.
    The Scottish Motor Neuron Disease Register: a prospective study of adult onset motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989. J Neurol Neurosurg Psychiatry 1992;55:536–541.
    OpenUrlAbstract/FREE Full Text
  32. 32.
    Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997: a population-based study. Neurology 1999;52:504–509.
    OpenUrlAbstract/FREE Full Text
  33. 33.
    Mitchell JD, Gatrell AC, Al-Hamad A, Davies RB, Batterby G. Geographical epidemiology of residence of patients with motor neuron disease in Lancashire and south Cumbria. J Neurol Neurosurg Psychiatry 1998;65:842–847.
    OpenUrlAbstract/FREE Full Text
  34. 34.
    Forsgren L, Almay BG, Holmgren G, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand 1983;68:20–29.
    OpenUrlCrossRefPubMed
  35. 35.
    Tysnes OB, Vollset SE, Aarli JA. Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway. Acta Neurol Scand 1991;83:280–285.
    OpenUrlPubMed
  36. 36.
    Jokelainen M. Amyotrophic lateral sclerosis in Finland. I: An epidemiologic study. Acta Neurol Scand 1977;56:185–193.
    OpenUrlPubMed
  37. 37.
    Hojer-Pedersen E, Christensen PB, Jensen NB. Incidence and prevalence of motor neuron disease in two Danish counties. Neuroepidemiology 1989;8:151–159.
  38. 38.
    Brewis M, Poskanzer DC, Rolland C, Miller H. Neurological disease in an English city. Acta Neurol Scand 1966;42(suppl):1–89
    OpenUrlPubMed
  39. 39.
    Kristensen O, Melgaard B. Motor neuron disease. Prognosis and epidemiology. Acta Neurol Scand 1977;56:299–308.
    OpenUrlPubMed
  40. 40.
    Gudmundsson KR. The prevalence of some neurological diseases in Iceland. Acta Neurol Scand 1968;44:57–69.
    OpenUrlPubMed
  41. 41.
    Mochecka-Thoelke A. Clinical pattern and epidemiological analysis of amyotrophic lateral sclerosis in the Lodz region in 1980–1986. Neurol Neurochir Pol 1994;28:189–194.
    OpenUrlPubMed
  42. 42.
    Gross-Paju K, Oopik M, Luus SM, et al. Motor neurone disease in South Estonia. Diagnosis and incidence rate. Acta Neurol Scand 1998;98:22–28.
  43. 43.
    Argyriou AA, Polychronopoulos P, Papapetropoulos S, et al. Clinical and epidemiological features of motor neuron disease in south-western Greece. Acta Neurol Scand 2005;111:108–113.
    OpenUrlCrossRefPubMed
  44. 44.
    Potemkowski A, Honczarenko K, Fabian A. [Clinical course and epidemiological analysis of amyotrophic lateral sclerosis in Szczecin in 1986–1995]. Neurol Neurochir Pol 1999;33:71–78.
    OpenUrlPubMed
  45. 45.
    Cendrowski W, Wender M, Owsianowski M.. [Epidemiological analysis of amyotrophic lateral sclerosis in Poznan District in Western Poland] Acta Neurol Scand 1970;46:609–617.
    OpenUrlCrossRefPubMed
  46. 46.
    Alcaz S, Jarebinski M, Pekmezovic T, Stevic-Marinkovic Z, Pavlovic S, Apostolski S. Epidemiological and clinical characteristics of ALS in Belgrade, Yugoslavia. Acta Neurol Scand 1996;94:264–268.
    OpenUrlPubMed
  47. 47.
    Chio A, Brignolio F, Meineri P, Rosso MG, Schiffer D. Epidemiology of motor neuron disease in two Italian provinces. Analysis of secular trend and geographic distribution. Neuroepidemiology 1989;8:79–86.
  48. 48.
    Lopez-Vega JM, Calleja J, Combarros O, Polo JM, Berciano J. Motor neuron disease in Cantabria. Acta Neurol Scand 1988;77:1–5.
    OpenUrlPubMed
  49. 49.
    Granieri E, Carreras M, Tola R, et al. Motor neuron disease in the province of Ferrara, Italy, in 1964–1982. Neurology 1988;38:1604–1608.
    OpenUrlAbstract/FREE Full Text
  50. 50.
    Bracco L, Antuono P, Amaducci L. Study of epidemiological and etiological factors of amyotrophic lateral sclerosis in the province of Florence, Italy. Acta Neurol Scand 1979;60:112–124.
    OpenUrlPubMed
  51. 51.
    Leone M, Chio A, Mortara P, Rosso MG, Schiffer D. Motor neuron disease in the Province of Turin, Italy, 1971–1980. Acta Neurol Scand 1983;68:316–327.
    OpenUrlCrossRefPubMed
  52. 52.
    Rosati G, Pinna L, Granieri E, et al. Studies on epidemiological, clinical, and etiological aspects of ALS disease in Sardinia, Southern Italy. Acta Neurol Scand 1977;55:231–244.
    OpenUrlPubMed
  53. 53.
    De Domenico P, Malara CE, Marabello L, et al. Amyotrophic lateral sclerosis: an epidemiological study in the Province of Messina, Italy, 1976–1985. Neuroepidemiology 1988;7:152–158.
    OpenUrlCrossRefPubMed
  54. 54.
    Yoshida S, Mulder DW, Kurland LT, Chu CP, Okazaki H. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. Neuroepidemiology 1986;5:61–70.
    OpenUrlCrossRefPubMed
  55. 55.
    McCluskey K, McCluskey L. Racial disparity in mortality from ALS/MND in US African Americans. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(suppl):73–78.
    OpenUrl
  56. 56.
    Noonan CW, White MC, Thurman D, Wong LW. Temporal and geographic variation in United States motor neuron disease mortality, 1969–1998. Neurology 2005;64:1215–1221.
    OpenUrlAbstract/FREE Full Text
  57. 57.
    Leone M, Chandra V, Schoenberg BS. Motor neuron disease in the United States, 1971 and 1973-1978: patterns of mortality and associated conditions at the time of death. Neurology 1987;37:1339–1343.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    Elian M, Dean G. Motor neuron disease and multiple sclerosis among immigrants to England from the Indian subcontinent, the Caribbean, and east and west Africa. J Neurol Neurosurg Psychiatry 1993;56:454–457.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    Kahana E, Alter M, Feldman S. Amyotrophic lateral sclerosis: a population study. J Neurol 1976;212:205–213.
    OpenUrlCrossRefPubMed
  60. 60.↵
    Chio A, Cucatto A, Calvo A, Terreni AA, Magnani C, Schiffer D. Amyotrophic lateral sclerosis among the migrant population to Piemonte, northwestern Italy. J Neurol 1999;246:175–180.
    OpenUrlCrossRefPubMed
  61. 61.
    Dean G, Elian M. Motor neuron disease and multiple sclerosis mortality in Australia, New Zealand and South Africa compared with England and Wales. J Neurol Neurosurg Psychiatry 1993;56:633–637.
    OpenUrlAbstract/FREE Full Text
  62. 62.
    Veiga-Cabo J, Almazan-Isla J, Sendra-Gutierrez JM, de Pedro-Cuesta J. Differential features of motor neuron disease mortality in Spain. Int J Epidemiol 1997;26:1024–1032.
    OpenUrlCrossRefPubMed
  63. 63.
    Neilson S, Robinson I, Hunter M. Static and dynamic models of interdisease competition: past and projected mortality from amyotrophic lateral sclerosis and multiple sclerosis. Mech Ageing Dev 1993;66:223–241.
    OpenUrlCrossRefPubMed
  64. 64.
    Martyn CN, Barker DJP, Osmond C. Motoneuron disease and past poliomyelitis in England and Wales. Lancet 1988;1:1319–1322.
  65. 65.
    Okamoto K, Kobashi G, Washio M, et al. Descriptive epidemiology of amyotrophic lateral sclerosis in Japan, 1995–2001. J Epidemiol 2005;15:20–23.
    OpenUrlCrossRefPubMed
  66. 66.
    Lima JMB, Mesquita N, Duro LAA, Furtado AB. Epidemiological aspects of amyotrophic lateral sclerosis in Rio de Janeiro city. Rev Bras Neurol 1983;19:75–78.
  67. 67.
    Kondo K, Tsubaki T. Changing mortality patterns of motor neuron disease in Japan. J Neurol Sci 1977;32:411–424.
    OpenUrlCrossRefPubMed
  68. 68.
    Gomes MM. Envelhecimento e o aumento das doencas amiotroficas: epidemiologia das doencas (cronicas) das celulas do corno anterior da medulla. Ar Qbras Med 1991;65:589–594.
    OpenUrl
  69. 69.↵
    Borak J, Fiellin M, Chemerynski S. Who is Hispanic? Implications for epidemiologic research in the United States. Epidemiology 2004;15:240–244.
    OpenUrlCrossRefPubMed
  70. 70.↵
    Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 1985;35:841–845.
    OpenUrlAbstract/FREE Full Text
  71. 71.
    Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality among minorities in the United States, 1990–2040. Neuroepidemiology 1994;13:179–186.
    OpenUrlPubMed
  72. 72.↵
    Gompertz B.. On the nature of the function expressive of the law of human mortality. Philos Trans R Soc Lond 1825;115:513–585.
    OpenUrlCrossRef
  73. 73.
    Neilson S, Robinson I, Alperovitch A.. Rising amyotrophic lateral sclerosis mortality in France 1968–1990: increased life expectancy and inter-disease competition as an explanation. J Neurol 1994;241:448–455.
    OpenUrlCrossRefPubMed

Disputes & Debates: Rapid online correspondence

  • Ethnic variation in the incidence of ALS: A systematic review
    • Joe Jacob Alappat, Neurology, Ibn Sina Hospital, Safat, Kuwaitjoealappat@yahoo.com
    Submitted April 24, 2007
  • Reply from the Authors
    • Orla Hardiman, Beaumont Hospital & RCSI, Dept. Neurology, Beaumont Hospital, Dublin 9, Irelandohard@iol.ie
    • Simon Cronin, Bryan J Traynor
    Submitted April 24, 2007
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Alert Me

  • Alert me when eletters are published

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise